Analyst consensus rating
Aardvark Therapeutics Analyst Rating: Buy
AARD is rated Buy by 10 analysts with a $14.50 target. As of 2026-08-26.
Direct answer
Aardvark Therapeutics's consensus rating is Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.50.
Forecast evidence checked August 26, 2026.
Get free Aardvark Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.25
- Average price target
- $14.50
- High price target
- $45.00
- Low price target
- $3.00
- Low target gap
- -58.6%
- Target upside
- +100%
- High target gap
- +520.7%
- Target range width
- 579.3%
- Consensus rating
- Buy
- Analysts
- 10
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aardvark Therapeutics?
Aardvark Therapeutics has a verified Buy consensus. The same dataset has an average price target of $14.50.
How far are Aardvark Therapeutics's low and high targets from the recorded price?
The low target implies -58.6%, while the high target implies +520.7%.
How many analysts are included in Aardvark Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Aardvark Therapeutics's target upside or downside calculated?
The average target of $14.50 is divided by the recorded price of $7.25, then one is subtracted to produce +100%. This does not guarantee a future return.
When was Aardvark Therapeutics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.